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ABSTRACT
Cervical screening by high-risk HPV (hrHPV) testing requires additional risk stratification (triage), as
most infections are transient and only a subset of hrHPV-positive women harbours clinically relevant
disease. Molecular triage markers such as microRNAs (miRNAs) and DNA methylation markers are
particularly promising, as they can be objectively tested directly on hrHPV-positive scrapes and
cervicovaginal self-samples. Here, we evaluated the marker potential of 10 candidate miRNAs in 209
hrHPV-positive scrapes of women with underlying precancer (cervical intraepithelial neoplasia, grade
2–3 (CIN2-3)), cancer, or without disease (CIN0/1). A predictive miRNA classifier for CIN3 detection was
built using logistic regression, which was compared to and combined with DNA methylation marker
FAM19A4. Markers were correlated to histology parameters and hrHPV genotype. A miRNA classifier
consisting of miR-149, miR-20a, and miR-93 achieved an area under the curve (AUC) of 0.834 for CIN3
detection, which was not significantly different to that of FAM19A4 methylation (AUC: 0.862, p =
0.591). Combining miRNA and methylation analysis demonstrated complementarity between both
marker types (AUC: 0.939). While the miRNA classifier seemed more predictive for CIN2, FAM19A4
methylation was particularly high in HPV16-positive and histologically advanced CIN3, i.e. CIN3 with
high lesion volume. The miRNA classifier, FAM19A4 methylation, and the miRNA/methylation combi-
nation were highest in cancer-associated scrapes. In conclusion, a panel of three miRNAs is discrimi-
natory for CIN3 in hrHPV-positive scrapes and can complement DNA methylation analysis for the
efficient detection of cervical disease. Combined analysis of the two marker types warrants further
evaluation as triage strategy in hrHPV-based screening.
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Introduction
Testing for high-risk human papillomavirus (hrHPV)
has recently replaced cytology as a primary screening
tool for cervical precancer and cancer in The
Netherlands and parts of Italy. Other countries are
soon to follow. While primary hrHPV testing has
a higher sensitivity for the detection of cervical disease
than cytology, it has a suboptimal specificity as it also
detects clinically irrelevant, transient infections [1,2].
The identification of hrHPV-positive women who are
in need of treatment, i.e. women with high-grade
cervical intraepithelial neoplasia (CIN2 and CIN3)
or cancer, therefore requires additional triage mar-
kers. Current triage strategies for hrHPV-positive
cervical scrapes include cytology and more objective,
molecular alternatives such as HPV16/18 genotyping
and analysis of DNA methylation markers [3].
Analysis of DNA methylation marker FAM19A4, for
instance, has shown convincing results for the triage
of hrHPV-positive cervical scrapes in the past [4].
Analysis of differential microRNA (miRNA)
expression for diagnostic and prognostic pur-
poses has gained increasing attention in recent
years. Others and we have previously shown
that differential miRNA expression between nor-
mal and cervical (pre)cancer cannot only be
detected in cervical tissue samples but also in
cervical exfoliated cells present in cervical scrapes
and self-collected cervico-vaginal specimens (self-
samples) [5–8]. Although the feasibility of
miRNA analysis for the triage of hrHPV-positive
women has been demonstrated, an optimal
miRNA panel for the detection of CIN3 and cer-
vical cancer still remains to be determined [6].
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Moreover, a direct comparison between miRNAs
and other molecular markers is currently missing.
In this study, the expression levels of 10 candidate
miRNAs (miR-15b, miR-125b, miR-149, miR-203a,
miR-375, miR-20a, miR-31, miR-93, miR-222, let-7b)
derived from an earlier feasibility study on cervical
scrapes and a study on hrHPV-positive self-samples
[6,8] were determined by qRT-PCR in 209 cervical
scrapes of hrHPV-positive women (age: 30–83 years)
with known underlying histology that have not been
tested for miRNAs before. A predictive miRNA clas-
sifier for the detection of CIN3 was built, which was
applied to the full sample series and subsequently
compared to and combined with the DNA methyla-
tion marker FAM19A4 [4]. Markers were correlated
to hrHPV genotype and histology parameters.
Results
miRNAs discriminate between CIN3 and CIN0/1 in
hrHPV-positive cervical scrapes
To assess miRNA expression in cervical scrapes
a study population obtained from an outpatient
cohort of hrHPV-positive women that was pre-
viously tested for DNA methylation of FAM19A4
[4] was used (n = 203). The study population was
supplemented with 27 cervical cancer patients. The
final study population consisted of 209 hrHPV-
positive cervical scrapes, as 21 samples (9%) did
not pass quality control (reference gene Ct value >
32, Figure 1).
Candidate miRNAs were selected as the clini-
cally most promising triage markers from previous
qRT-PCR studies performed on (1) hrHPV-
positive scrapes (miR-125b, miR-149, miR-203a,
and miR-375) or (2) hrHPV-positive self-samples
(miR-20a, miR-31, miR-93, miR-222, let-7b)
obtained from screening cohorts [6,8]. miR-15b
was derived from both studies. miRNAs selected
from (1) were previously identified using miRNA
microarray analysis of cervical tissue samples and
shown to be either genetically (miR-15b) or epi-
genetically (miR-125b, miR-149, miR-203a, miR-
375) regulated [9,10], while miRNAs from
approach (2) were identified following small
RNA sequencing directly performed on hrHPV-
positive self-samples [8].
Figure 1. Overview of the study population.
hrHPV, high-risk human papillomavirus; CIN, cervical intraepithelial neoplasia; SCC, squamous cell carcinoma; AC, adenocarcinoma.
EPIGENETICS 559
Supplemental Figure 1 shows the expression levels
of the 10 candidate miRNA markers in the different
biological groups, i.e. CIN0/1, CIN2, CIN3, squamous
cell carcinoma (SCC), and adenocarcinoma (AC). All
miRNAs, with the exception of miR-31, were signifi-
cantly differentially expressed between the histological
groups (Kruskal–Wallis: p < 0.05). Since the classifi-
cation of CIN2 is ambiguous [11] we compared
CIN0/1 to CIN3. Eight miRNAs, i.e. miR-15b, miR-
125b, miR-149, miR-203a, miR-375, let-7b, miR-93,
andmiR-222, showed significantly differential expres-
sion between CIN0/1 and CIN3 (Wilcoxon,
Benjamini-Hochberg: p < 0.05). To evaluate the dis-
criminatory power of individual miRNAs for CIN3,
we next performed univariate logistic regression on
data obtained from 77 CIN0/1 and 55 CIN3.
Obtained AUCs ranged from 0.571 (miR-20a) to
0.743 (miR-125b, Table 1). Robustness of the indivi-
dual miRNAs was demonstrated by comparable
AUCs achieved after leave-one-out cross-validation
(LOOCV).
To identify the combination of miRNAs with the
highest discriminatory power for CIN3, we performed
multivariate logistic regression on data obtained from
CIN0/1 and CIN3. The optimal miRNA classifier
consisted of miR-149, miR-20a, and miR-93, and
achieved an AUC of 0.834 (Figure 2a), which was
higher than AUCs achieved by individual miRNAs.
Following LOOCV, an AUC of 0.808 was obtained,
indicating robustness of the miRNA classifier.
Including more miRNAs in the classifier did not
improve detection of CIN3 (data not shown).
Applying the 3-miRNA classifier to the full sample
series, predicted probabilities representing the risk of
an underlying CIN3 were assigned to each sample.
A clear increase in predicted probabilities with disease
severity was observed (Figure 2b). Carcinoma sam-
ples, in particular, had very high predicted probabil-
ities, indicating that the 3-miRNA classifier would
also allow for the detection of cervical cancer even
Figure 2. Performance of the 3-miRNA classifier for the detection of cervical disease. (a) Results obtained from 77 hrHPV-positive
scrapes from women without underlying disease (CIN0/1) and 55 scrapes from women with CIN3 were used to build a 3-miRNA
classifier for the detection of CIN3. The diagonal line indicates an AUC of 0.5. (b) Predicted probabilities (i.e. risk of CIN3; value range
0 to 1) obtained for all samples using the 3-miRNA classifier.
AUC, area under the curve; CIN, cervical intraepithelial neoplasia; SCC, squamous cell carcinoma; AC, adenocarcinoma.
Table 1. Performance of individual miRNAs for the detection of
CIN3 in cervical scrapes. Robustness of the individual miRNAs
was evaluated using LOOCV.
miRNA AUC AUC (LOOCV)
miR-15b 0.619 0.588
miR-125b 0.743 0.727
miR-149 0.723 0.703
miR-203a 0.704 0.677
miR-375 0.647 0.621
let-7b 0.724 0.704
miR-20a 0.571 0.525
miR-31 0.625 0.593
miR-93 0.671 0.648
miR-222 0.623 0.572
CIN, cervical intraepithelial neoplasia; LOOCV, leave-one-out cross-validation.
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though these were not included in the building of the
model.
Combined analysis of miRNA expression and
DNA methylation improves CIN3 detection
To allow for a direct comparison between the miRNA
classifier and the DNA methylation marker
FAM19A4, predicted probabilities were calculated
for the previously obtained FAM19A4 methylation
data [4] using univariate logistic regression analysis.
In the same set of samples, the AUC of FAM19A4
methylation analysis (0.862, LOOCV: 0.849) was not
significantly different to that of the 3-miRNA classi-
fier (DeLong: p = 0.591, Figure 3a).We next evaluated
the potential complementarity between miRNA and
methylation analysis for the detection of CIN3. To
this end, a classifier was built based on the three
miRNAs from the 3-miRNA classifier and
FAM19A4 methylation. Multivariate logistic regres-
sion was performed on data obtained from CIN0/1
and CIN3. In the combined model all three miRNAs
and FAM19A4methylation were retained. The model
achieved an AUC of 0.939 (LOOCV: 0.918; Figure 3a)
and had a significantly better performance than the
3-miRNA classifier (DeLong: p = 0.0003) or
FAM19A4 methylation alone (DeLong: p = 0.007).
This indicates that miRNA and methylation markers
are to a certain extent complementary and identify
a slightly different subset of CIN3 lesions. When
applying the combined miRNA/methylation classifier
to the full sample series, including CIN2, SCC, and
AC samples, the predicted probabilities were found to
increase with cervical disease severity (Figure 3b).
Compared to the 3-miRNA classifier (Figure 2b),
the combined classifier generally assigned lower pre-
dicted probabilities to CIN0/1, while the majority of
CIN3 lesions obtained very high predicted probabil-
ities. This led to a better separation between the two
groups, in line with the higher AUC. Cervical SCC
and AC were characterized by predicted probabilities
close to 1, indicating that a combinedmiRNA/methy-
lation classifier is highly discriminatory for cervical
carcinomas.
miRNA and methylation results in relation to
clinical and viral parameters
In an attempt to further compare the different classi-
fiers, underlying CIN2 and CIN3 lesions were strati-
fied (1) by lesion volume into low- and high-volume
lesions [12] (Figure 4a) and (2) by hrHPV type into
Figure 3. Performance of the combined miRNA/methylation classifier for the detection of cervical disease. (a) Results obtained from
77 hrHPV-positive scrapes from women without underlying disease (CIN0/1) and 55 scrapes from women with CIN3 were used to
build a FAM19A4 methylation classifier [4] and a combined miRNA/methylation classifier for the detection of CIN3. The diagonal line
indicates an AUC of 0.5. There was no significant difference between the 3-miRNA classifier and FAM19A4 methylation analysis
(DeLong: p = 0.591). The miRNA/methylation classifier performed significantly better than the 3-miRNA classifier (DeLong: p =
0.0003) and FAM19A4 methylation analysis (DeLong: p = 0.007). (b) Predicted probabilities (i.e. risk of CIN3; value range 0 to 1)
obtained for all samples using the combined miRNA/methylation classifier.
AUC, area under the curve; CIN, cervical intraepithelial neoplasia; SCC, squamous cell carcinoma; AC, adenocarcinoma.
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HPV16, HPV18, and other hrHPV types (Figure 4b).
The predicted probabilities of the miRNA classifier
were slightly increased in high-volume lesions com-
pared to low-volume lesions in both CIN2 and CIN3
(Figure 4a). Predicted probabilities obtained with
FAM19A4 methylation and the miRNA/methylation
classifier, on the other hand, were significantly
increased in the high-volume CIN3 lesions and no
relation to lesion size was seen within CIN2 lesions.
Stratification of CIN2 and CIN3 lesions by hrHPV
type indicated a trend towards higher predicted prob-
abilities for FAM19A4 and the combined miRNA/
methylation classifier in cervical scrapes with HPV16-
positive underlying CIN3 lesions compared to non-16
Figure 4. 3-miRNA classifier and FAM19A4 methylation in relation to lesion volume of CIN2 and CIN3 lesions and hrHPV genotype.
Predicted probabilities obtained by the 3-miRNA classifier, FAM19A4 methylation analysis, or the combined miRNA/methylation
classifier in hrHPV-positive cervical scrapes of women with CIN2/3, stratified by A lesion size (lesion size was not available for 5 CIN2
and 1 CIN3) and B hrHPV type. (Partial) hrHPV genotyping was performed on the same cervical scrape used for miRNA expression
and FAM19A4 methylation analysis. ** p < 0.005.
CIN, cervical intraepithelial neoplasia.
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hrHPV type-associated CIN3 (Figure 4b). There were
no clear differences between hrHPV types with the
3-miRNA classifier, FAM19A4, or the combined
miRNA/methylation classifier in other histological
groups (data not shown).
Discussion
The use ofmolecularmarkers for the triage of hrHPV-
positive women is objective and may allow for high-
throughput analysis of large numbers of cervical sam-
ples. In this study, we evaluated 10 candidate miRNA
triagemarkers and comparedmiRNA expression ana-
lysis to the DNA methylation marker FAM19A4.
Logistic regression was used to build a 3-miRNA clas-
sifier with high discriminatory power for CIN3. We
demonstrate that miRNA expression analysis is com-
plementary to FAM19A4 methylation and that com-
bining miRNA expression and DNA methylation
analysis improves detection of CIN3.
In general, higher predicted probabilities were
obtained in CIN2 using the 3-miRNA classifier com-
pared to the combinedmiRNA/methylation classifier,
whereas in CIN3 the reverse was seen. Further strati-
fication of CIN2 and CIN3 lesions by lesion volume
showed that the highest predicted probabilities were
obtained in CIN3 lesions with a high volume when
using FAM19A4 methylation. This is in line with
previous data demonstrating the highest methylation
levels in advancedCIN3 [13]. Importantly, when com-
bining miRNA and methylation analysis, both CIN2
and CIN3 lesions were captured. Stratification of
CIN2 and CIN3 lesions by hrHPV type, moreover,
indicated thatmethylation of FAM19A4 is particularly
high in HPV16-associated CIN3. Interestingly,
increased methylation levels of ASCL1, LHX8, and
ST6GALNAC5 in HPV16-compared to other hrHPV
type-associated CIN3 lesions and cervical carcinomas
have recently been reported in a South African study
cohort of women living with HIV [14].
Hypermethylation of host cell genes in cervical carci-
nogenesis has been linked to HPV16 E6 and E7
mediated upregulation of the DNAmethyltransferase
DNMT1 [15,16]. The high carcinogenic potential of
HPV16may, therefore, relate to its capacity to activate
DNMT1. Because studies on the effect of other hrHPV
types on DNMT1 and other methyl transferases are
currently missing, this notion warrants further
investigation.
The 10 candidate miRNAs analysed in this study
have previously been investigated as triage markers
in either hrHPV-positive scrapes, hrHPV-positive
self-samples, or both, and current data on 8 out of
the 10 analysed miRNAs showed good concordance
with previous results [6,8]. The optimal miRNA
panel for detection of CIN3 consisted of miR-149,
miR-20a, and miR-93. The most discriminatory
individual miRNA marker (miR-125b) was not
selected by our statistical analysis in the final
miRNA classifier, which illustrates that combining
a few complementary miRNAs has benefits for the
detection of CIN3 over selecting the seemingly best
miRNA markers.
In cervical cancer cell lines SiHa and HeLa, miR-
149 has been shown to act as tumour suppressor by
inhibiting proliferation and promoting apoptosis
[17]. Both miR-20a and miR-93 belong to the miR-
17–92 family, a highly conserved, polycistronic clus-
ter of miRNAs. MiRNAs belonging to the mir-17–92
have been associated to carcinogenesis, in particular
by inhibition of apoptosis via E2F transcription fac-
tors, and are therefore referred to as oncomiR-1
cluster [18,19]. In cervical cancer, both miR-20a
and miR-93 have been shown contribute to disease
progression [20–24]. This indicates that the miRNAs
in our 3-miRNA classifier are biologically relevant in
cervical carcinogenesis.
Due to their short length, miRNAs are considered
to be very stable molecules that can be successfully
detected even in degraded RNA preparations [25].
Analysis of differentially expressed miRNAs might,
therefore, be especially promising in low-resource
settings, where sample quality is compromised as
a result of storage and transportation under subopti-
mal conditions. In our study, miRNA expression
analysis of 10 targets and two reference genes was
performed from low amounts of clinical material, i.e.
20 ng small RNA, and the invalid rate due to high
reference gene Ct values was low (3%), highlighting
the value of miRNA expression analysis in cervical
scrapes. Considering that miRNA expression and
DNA methylation analysis currently require two
individual workflows, i.e. RNA isolation, reverse
transcription, and qPCR or DNA isolation, bisulfite-
conversion, and qMSP, respectively, we acknowledge
that combined analysis of miRNAs and methylation
markers in its current format is not practical. While
simultaneous analysis of the transcriptome (mRNA)
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and DNA methylome is feasible at rather high costs
for limited numbers of samples at present [26,27],
advancing (targeted) sequencing techniques might
allow for simultaneous analysis ofmiRNAexpression
and DNA methylation at moderate prices in the
future.
A limitation of the study is that for the purpose of
a direct comparison between miRNA and DNA
methylation markers we used a selected series of
cervical samples from women referred to
a gynecological outpatient clinic, and only included
CIN0/1 lesions with normal cytology as controls.
Therefore, the results cannot be directly translated
to a screening setting and further studies are war-
ranted. Moreover, FAM19A4 was the only DNA
methylation marker investigated. Recent studies,
however, have described other promising DNA
methylation markers for hrHPV-based screening
that remain to be tested in combination with differ-
entially expressed miRNAs [28,29].
In conclusion and to the best of our knowledge, this
is the first study on combining miRNA and methyla-
tion markers for the detection of cervical disease. This
study shows that miRNA expression can complement
DNA methylation analysis for the efficient detection
of cervical disease on hrHPV-positive cervical scrapes,
and that combined analysis improves detection of
CIN3 lesions. Our data suggest that molecular testing
of cervical scrapes offers a promising triage strategy in
hrHPV-based screening.
Materials & methods
Study population and HPV testing
The sample series included cervical scrapes of
hrHPV-positive women between 30 and 70 years of
age who participated in a gynecological outpatient
study between December 2010 and December 2013.
Detailed characteristics, inclusion criteria, and follow-
up procedures have been described previously [4].
FAM19A4 methylation status and HPV genotyping
have previously been reported [4]. The study cohort
comprised 56 CIN2, 64 CIN3 (including 2 adenocar-
cinomas in situ (AIS)), 1 SCC, and 2 AC (including 1
adenosquamous carcinoma (ASC)), of which the cor-
responding hrHPV-positive cervical scrapes were
included in this study (Figure 1). Moreover, hrHPV-
positive cervical scrapes of women without cervical
disease (CIN0, n = 55) or with underlying CIN1 (n =
25), which had normal cytology (Pap1) and who were
not referred to the outpatient clinic based on abnor-
mal cytology in a previous scrape were included as
controls. Absence or presence of underlying disease
was histologically confirmed for all samples.
Histological outcomes were based on colposcopy-
directed biopsies, or, if classified worse, on the histol-
ogy result of the specimen excised by LLETZ, conisa-
tion, or hysterectomy.
Additionally, we included hrHPV-positive scrapes
of women with underlying SCC (n = 24) and AC (n =
3) who underwent treatment for cervical cancer at the
Center for Gynecological Oncology Amsterdam
(Amsterdam University Medical Center, location
AMC and VUmc, and Antoni van Leeuwenhoek
Hospital), Amsterdam, The Netherlands, between
October 2016 and December 2017. These samples
were tested for hrHPV using the HPV-Risk Assay
(Self-screen B.V.), providing partial genotyping
results [30,31].
Of the 230 hrHPV-positive cervical scrapes, 21
were excluded based on quality control for either
miRNA expression analysis, DNA methylation ana-
lysis, or both (Figure 1). The final study cohort there-
fore consisted of 209 scrapes comprised of 52
underlying CIN0 (median age: 39.5 years, range:
31–63), 25 CIN1 (median age: 35.0 years, range:
30–66), 48 CIN2 (median age: 34.5 years, range:
30–56), 55 CIN3 (including 2 AIS, median age: 35.0
years, range: 30–60), 24 SCC (median age: 48.5 years,
range: 30–83), and five AC (including 1 ASC, med-
ian age: 50.0 years, range: 36–63).
RNA isolation and quantitative RT-PCR
Total RNA was isolated using TRIzol reagent
(Thermo Fisher Scientific) according to the manufac-
turer’s instructions. The Qubit® microRNA Assay kit
was used to quantify small RNA concentrations on
a Qubit® 2.0 Fluorometer (both Thermo Fisher
Scientific).
Expression of hsa-let-7b-5p, hsa-miR-15b-5p,
hsa-miR-125b-5p, hsa-miR-149-5p, hsa-miR-20a-
5p, hsa-miR-203a-3p, hsa-miR-222-3p, hsa-miR
-31-5p, hsa-miR-375, and hsa-miR-93-5p was mea-
sured using TaqMan microRNA assays (002619,
000390, 000449, 002255, 000580, 000507, 002276,
002279, 000564, 001090; Thermo Fisher Scientific).
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RNU24 and hsa-miR-423-3p were included as
reference genes as these were previously found to
be most stable in this sample type (001001, 002626;
Thermo Fisher Scientific) [6,32].
Reverse transcription (RT) was multiplexed by
combining specific RT primers for all targets as
a primer pool. cDNA was synthesized from 20 ng
small RNA template if available. For 37 samples the
maximum possible amount (<20 ng) of RNA was
used, of which 7 (19%) did not pass quality control.
Each 16 µl reaction contained 6 µl primer pool, 0.3 µl
dNTPs (100mM), 1.5 µl RT buffer, 0.19 µl RNase
inhibitor (20 U/µl) and 3 µl MultiScribe Reverse
Transcriptase (TaqMan microRNA Reverse
Transcription kit, Thermo Fisher Scientific).
Quantitative PCR reactions were performed on the
ViiA7TM Real-Time PCR System (Thermo Fisher
Scientific) in a 384-well format. Each 10 µl reaction
consisted of 5 µl TaqMan®UniversalMasterMix II, 0.5
µl miRNA specific TaqMan assays (both Thermo
Fisher Scientific), 3.5 µl H2O and 1 µl cDNA. Cycle
conditions for cDNA synthesis and PCR were used
according to the manufacturer’s protocols.
Data were normalized to the geometric mean Ct of
RNU24 and hsa-miR-423-3p applying the 2ΔCt
method [33]. Samples with a geometric mean Ct of
RNU24 and hsa-miR-423 ≥ 32 did not pass quality
control.
DNA isolation and FAM19A4 methylation
analysis
Cervical scrapes originating from an outpatient
cohort had previously been tested for FAM19A4
methylation [4]. Data were normalized to ACTB
using the 2ΔCt method [33]. To ensure sample
quality, samples with an ACTB Ct value ≥32
were excluded from the final study cohort. For
the additional cervical scrapes from cervical can-
cer patients, DNA was extracted using the
NucleoMag 96 Tissue kit (Macherey-Nagel) and
a Microlab Star robotic system (Hamilton)
according to the manufacturer’s protocol.
Extracted DNA was subjected to bisulphite-
conversion using the EZ DNA Methylation Kit
(Zymo Research). For FAM19A4 methylation
analysis, the QIAsure Methylation Test (Self-
screen B.V.) was used.
Statistical analysis
To compare miRNA expression levels between CIN0/
1, CIN2, CIN3, SCC, andAC, we performed an omni-
bus Kruskal–Wallis test followed by a Wilcoxon rank
test with a significance level of 0.05 (two-sided) when
the omnibus test showed a significant result (p < 0.05).
P-values from the post-hoc test were corrected with
the Benjamini-Hochberg correction method. Because
screening programs are designed to identify and treat
high-grade CIN to prevent cervical cancer, logistic
regression was performed on square root transformed
delta Ct ratios obtained from CIN0/1 (controls) and
CIN3 lesions (cases). CIN2 lesions were not included
in logistic regression analysis, as their classification is
ambiguous [11]. Univariate logistic regression was
performed to evaluate the discriminatory power of
individual miRNAs and FAM19A4 methylation ana-
lysis.Multivariate logistic regression followed by back-
ward elimination was used to identify the optimal
multi-miRNA classifier and to build a combined
miRNA/methylation classifier for the detection of
CIN3. As a result of univariate and multivariate logis-
tic regression, predicted probabilities, i.e. values
between 0 and 1 representing the risk of an underlying
CIN3, were assigned to each sample. Receiver-
operated characteristic (ROC) curve analysis was car-
ried out to evaluate the performance of the miRNA
classifiers in detecting CIN3. Robustness of the classi-
fiers was evaluated using leave-one-out cross-
validation (LOOCV). For comparison of the obtained
AUCs DeLong’s test for two correlated ROC curves
was used [34]. The resulting multi-marker classifiers
were subsequently applied on data obtained from
CIN2 and carcinoma samples.
Stratification of CIN2 and CIN3 lesions
In an attempt to stratify CIN2 and CIN3 lesions
in relation to lesion size, a rough estimation of
the lesion volume (low/high) was used [12]. In
short, a biopsy diagnosed as a CIN2 or CIN3
lesion was classified as high-volume if the histo-
logical outcome of the corresponding LLETZ (or
conisation/hysterectomy) specimen was ≥CIN2
or ≥CIN3, respectively. A biopsy diagnosed as a
CIN2 or CIN3 lesion was considered low-volume
if the paired LLETZ had a lower histological out-
come, i.e. ≤CIN1 or ≤CIN2, respectively. Biopsy
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specimens of high-grade CIN for which no
LLETZ was performed (according to physician’s
advice) were classified as low-volume. Moreover,
CIN2 and CIN3 lesions were also stratified
according to hrHPV genotypes. For this purpose,
multiple infections including HPV16 or HPV18
were categorized as HPV16-positive or HPV18-
positive, respectively, and multiple infections
containing both HPV16 and HPV18 were
assigned to the HPV16-positive group [35].
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